BIOGEN INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 202.6 USD | +0.31% |
|
+6.37% | -21.68% |
| 02:57pm | Goldman Sachs Adjusts Biogen Price Target to $340 From $393 | MT |
| 02:39pm | Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- With an enterprise value anticipated at 3.45 times the sales for the current fiscal year, the company turns out to be overvalued.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -21.68% | 29.36B | B- | ||
| -2.86% | 87.31B | A- | ||
| +2.63% | 40.86B | A- | ||
| +58.56% | 24.49B | A | ||
| -14.35% | 17.31B | C | ||
| -18.94% | 11.62B | B- | ||
| -15.61% | 11.31B | D+ | ||
| -44.02% | 11.26B | B | ||
| +5.17% | 8.31B | B+ | ||
| -9.82% | 7.9B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIIB Stock
- Ratings Biogen Inc.
